A Biomarker Blood Test Could Tell You If Your Treatment Works. But Most Patients Never Get It.

It sounds like science fiction. A simple blood draw. A few days later, your doctor knows exactly which treatment will work and which one will waste your time while your cancer grows. It is not science fiction. It already exists. And most breast cancer patients are still not getting tested for it.

In January 2026, researchers at the Institute of Cancer Research  published a

study that should have made headlines everywhere. They used a liquid biopsy, a blood test that measures circulating tumor DNA, to predict whether a breast cancer treatment would actually work before it even started. The results were striking.

Patients with low ctDNA before treatment survived without their cancer progressing for 10.2 months. Those with high ctDNA made it 4.4 months. That is not a marginal difference. That is six extra months of life. For some, after a single treatment cycle, undetectable ctDNA meant 12 months of progression-free survival versus just over 4 months.

This is the future of oncology. And it is sitting in a lab that most patients will never get referred to.

The Problem Is Not the Science. The Problem Is Access.

Biomarker testing is no longer just ER, PR, and HER2 anymore. The landscape has expanded fast and it keeps expanding. In Q1 of 2026 alone, multiple breakthrough studies have reshaped what we know about breast cancer biology.

A study published in Docwire News examined data from the SERENA-6 and PADA-1 trials, showing that circulating tumor DNA can detect ESR1 mutations in real time and guide treatment switches before a patient even starts progressing. This means a blood test can tell your oncologist it is time to change therapy before the cancer has a chance to spread. Nobody is using this widely enough.

Nature Communications published work in March 2026 on integrating liquid biopsies with tissue signatures to predict treatment response to giredestrant in ER-positive breast cancer. They proved that multimodal biomarker profiling can personalize endocrine therapy. It works. It is just not the standard of care.

And Cancer Network's update from Dr. Tolaney at Dana-Farber laid out the full biomarker landscape now relevant in breast cancer: ESR1, PIK3CA, PTEN, PD-L1, BRCA, NTRK, tumor mutation burden, and microsatellite instability-high. That is not a manageable checklist. That is a comprehensive genomic profiling requirement. And most sites are still not doing it.

Here Is What Most Patients Actually Experience

A woman gets diagnosed. Her tumor is tested for the basics, ER, PR, HER2. Those come back and she gets put on a standard regimen. Nobody orders extended genomic profiling because her site does not do it routinely. Nobody checks for PIK3CA, ESR1, BRCA germline, PD-L1, or NTRK alterations. Nobody measures her ctDNA to see if the treatment is even working.

Three months later, her scans come back and the cancer has grown. She gets switched to another drug. Then another. Each time, the same guess-and-check cycle, and each time, the window for effective intervention gets smaller.

By the time someone finally orders a biomarker panel, she may no longer be strong enough for the targeted therapy that could have saved her.

This is not a rare story. It is the standard story. And it is completely preventable.

What Needs to Change

We have the tests. We have the drugs. The gap is in trial and clinical design, the operational piece that connects the right patient to the right intervention at the right time.

Ten years in clinical research has taught us one thing above all else: the science moves faster than the system that delivers it. Every time a new biomarker gets validated, it takes years to become routine at community sites. By the time it gets there, another generation of patients has been treated like the markers do not even exist.

Rubix LS was built because of this gap. We do not just design trials. We design them around how patients actually move through the system, not how sponsors imagine they will. That means biomarker testing at day one, not day ninety. It means site-level readiness, not just protocol mandates on paper. It means building the operational infrastructure so the blood test actually reaches the patient who needs it.

Because without that, the science does not matter. Having a cure means nothing if the person who needs it never gets the test that would have sent them there.

We Need to Stop Treating Biomarker Testing Like a Luxury Add-On

It should be the first thing, not the last.

If your site is running breast cancer trials and is not doing comprehensive biomarker profiling from day one, you are running 2026 trials with 2016 infrastructure. The patients in your trial right now deserve better than that.

Let us fix it.

If your site needs help operationalizing this, Rubix LS builds trials that work. Learn more: rubixls.com. #BiomarkerTesting #PrecisionOncology #ClinicalTrials